251 related articles for article (PubMed ID: 31236688)
41. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
Arrese M; Accatino L
Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
[TBL] [Abstract][Full Text] [Related]
42. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
[TBL] [Abstract][Full Text] [Related]
43. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.
Wimmer R; Hohenester S; Pusl T; Denk GU; Rust C; Beuers U
Gut; 2008 Oct; 57(10):1448-54. PubMed ID: 18583398
[TBL] [Abstract][Full Text] [Related]
44. Effect of bile acids on ischemia-reperfusion liver injury.
Chazouillères O; Ballet F; Legendre C; Bonnefis MT; Rey C; Chrétien Y; Poupon R
J Hepatol; 1991 Nov; 13(3):318-22. PubMed ID: 1808225
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
46. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes.
Benz C; Angermüller S; Otto G; Sauer P; Stremmel W; Stiehl A
Eur J Clin Invest; 2000 Mar; 30(3):203-9. PubMed ID: 10691996
[TBL] [Abstract][Full Text] [Related]
47. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
48. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation.
Uchida A; Yamada T; Hayakawa T; Hoshino M
Am J Physiol; 1997 May; 272(5 Pt 1):G1249-57. PubMed ID: 9176237
[TBL] [Abstract][Full Text] [Related]
49. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Urbani G; Morretta E; Monti MC; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159218. PubMed ID: 35985473
[TBL] [Abstract][Full Text] [Related]
50. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
[TBL] [Abstract][Full Text] [Related]
51. Secondary bile acids and the biliary epithelia: The good and the bad.
Lenci I; Milana M; Signorello A; Grassi G; Baiocchi L
World J Gastroenterol; 2023 Jan; 29(2):357-366. PubMed ID: 36687129
[TBL] [Abstract][Full Text] [Related]
52. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
53. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
54. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
55. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes.
Benz C; Angermüller S; Töx U; Klöters-Plachky P; Riedel HD; Sauer P; Stremmel W; Stiehl A
J Hepatol; 1998 Jan; 28(1):99-106. PubMed ID: 9537871
[TBL] [Abstract][Full Text] [Related]
56. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
[TBL] [Abstract][Full Text] [Related]
57. TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway.
Baiocchi L; Tisone G; Russo MA; Longhi C; Palmieri G; Volpe A; Almerighi C; Telesca C; Carbone M; Toti L; De Leonardis F; Angelico M
Transpl Int; 2008 Aug; 21(8):792-800. PubMed ID: 18435680
[TBL] [Abstract][Full Text] [Related]
58. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways.
Schoemaker MH; Conde de la Rosa L; Buist-Homan M; Vrenken TE; Havinga R; Poelstra K; Haisma HJ; Jansen PL; Moshage H
Hepatology; 2004 Jun; 39(6):1563-73. PubMed ID: 15185297
[TBL] [Abstract][Full Text] [Related]
59. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
60. Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.
Ueda H; Honda A; Miyazaki T; Morishita Y; Hirayama T; Iwamoto J; Nakamoto N; Ikegami T
PLoS One; 2022; 17(7):e0271308. PubMed ID: 35819971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
